Biogen (BIIB) – Reuters
-
Biogen cost cuts drive profit beat, as Alzheimer's drug off to slow start
-
Biogen sees flat 2024 sales, pick up in Alzheimer's drug demand
-
Biogen drops Alzheimer's drug Aduhelm, ending a 17-year chapter
-
Biogen cuts annual profit forecast on higher deal costs (Nov 8)
-
Biogen announces job cuts, turns focus to Alzheimer's drug launch
-
Biogen shareholders back Susan Langer as director
-
Biogen rises as FDA panel backs Alzheimer's drug, easing safety concerns
-
Biogen trims pipeline programs to cut costs, focus on Alzheimer's drug launch
-
Alzheimer's Association lobbies for Medicare coverage of Leqembi and other drugs
-
Biogen CEO bets on Alzheimer's drug, pipeline to return to growth
-
Eisai, Biogen get U.S. FDA approval for Alzheimer's drug, apply for full approval
-
Alzheimer's drug from Eisai and Biogen slows cognitive decline, side-effects in focus
-
Roche's Alzheimer's drug fails to meet goal in long awaited trial
-
Biogen hires former Sanofi head Viehbacher as CEO
-
Biogen confident in Alzheimer's drug ahead of rivals' data
-
Former J&J executive emerges as front-runner for Biogen top job - STAT News
-
Analysis-Alzheimer's drug breakthrough big boost for Roche, Eli Lilly
-
Biogen shares soar on landmark Alzheimer's data, lift rivals
-
U.S. FDA accepts Biogen's ALS therapy for review
-
Biogen leans on new Alzheimer's drug to calm investor worries
-
Sage-Biogen drug improves symptoms in postpartum depression study
-
Biogen CEO to leave as Alzheimer's drug struggles
-
Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm
-
Biogen says U.S. FTC, SEC probing Alzheimer's disease drug
-
Biogen's 2022 forecast well below Street view on Alzheimer's drug uncertainty
-
Biogen eyes potential acquisitions - Stat News
-
Biogen shares slide as Medicare proposal restricts coverage of Alzheimer's treatments
-
U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patients
-
Medicare asked to reassess 2022 premium hikes after Aduhelm price cut
-
Samsung BioLogics says report on Biogen deal talks untrue
-
Biogen's Alzheimer's drug gets negative European panel vote
-
Biogen banks on government coverage to restart stalled Alzheimer's drug sales
-
Biogen sales face pressure from slow uptake of Alzhiemer's drug
-
U.S. Congress seeks information from FDA on approval of Biogen's Alzheimer's drug
-
Biogen provides free Aduhelm as U.S. clinics await Medicare payment
-
Buffett's Berkshire pares drug holdings, sheds Axalta, Biogen
-
Biogen says uptake on new Alzheimer's drug slower than expected
-
Biogen Alzheimer's drug slow to take off as U.S. Medicare wrestles with coverage
-
Biogen Alzheimer's drug hits roadblocks with some hospitals, insurers
-
UnitedHealth says needs more information to decide on coverage policy for Biogen's Alzheimer's drug - CEO
-
U.S. starts national Medicare coverage policy review for Biogen's Aduhelm
-
FDA seeks probe into its talks with Biogen before Alzheimer's drug approval
-
Eisai's drug for Alzheimer's with Biogen gets breakthrough status in U.S
-
First patient receives controversial Biogen Alzheimer's drug
-
Biogen to start shipping Alzheimer's drug in about two weeks
-
Investors, patients await FDA decision on Biogen Alzheimer's drug due Monday
-
Biogen plunges 30% after FDA panel votes against Alzheimer's drug
-
Energy, travel stocks surge on Pfizer vaccine hopes
-
U.S. experts to review Biogen drug that could be first new Alzheimer's treatment in decades
-
Biogen, gene-editing startup Scribe to develop therapies for Lou Gehrig's disease
Back to BIIB Stock Lookup
